Rapid Infuser Market

Use in Operative Hypothermia

According to the Journal of Trauma Nursing, the use of rapid infusers with warming is a viable practice for whole blood product infusions, with the aim of preventing hyperthermia associated to transfusions. 

Patients suffering from acute blood loss or anemia are prone to hypothermia, which can result in coagulopathy.

High expenses arising from complexities in surgeries, infections in surgery sites, and delays in recovery are potential results from hypothermia. Consequently, in cases of trauma or blood loss during surgery, the requirement for rapid infusers for transfusions of warm blood and other crystalloid fluids is critical. This trend is likely to sustain market growth for the foreseeable future.

Massive Transfusion Applications Drive Demand

Massive transfusion is the practice of transfusing 10 or more RBC products within a period of 24 hours, which has become increasingly mainstream amidst pediatric patients.

It is crucial for time-restrained operations where blood typing cannot be completed. The transfusion of AB plasma and O RBCs through rapid infusers will remain critical in such emergency procedures.

According to the CDC, 2019 saw more than 48 million surgical and non-surgical procedures. This has resulted in a substantial demand for blood, plasma, and crystalloid fluids, many of which require rapid infusers. Similar statistics in other parts of the globe, indicate potential for sustained growth in the near future.

Ambulatory Healthcare Facilities Create Opportunities

In 2019, over half of all ambulatory surgery procedures were conducted in hospitals, with the remaining being performed in ASCs. Rapid infusers provide efficient and fast, fluid delivery in myriad emergency health settings.

Also, aggressive and early fluid therapy has been found to be very effective for interventions associated with critical ailments such as sepsis, and major trauma. Rapid infusers are capable of significant recovery in body vitals such as heart rate in a matter of minutes. These factors are likely to drive adoption from ASCs with a moderate growth rate of nearly 3.5% CAGR.

Key Challenges

Rapid infuser devices are rapidly becoming mainstream in hospitals and specialist clinics around the world. However, market players are likely to face growing challenges during the assessment period. The high cost of conventional rapid infusion devices is a major concern hindering adoption.

Also, slow adoption of rapid infusion devices in hospitals, especially in developing countries and rural areas owing to poor awareness, hurts market prospects. The covid-19 pandemic is also likely to limit sales as healthcare facilities redirect resources to handle the outbreak.

Region-wise Analysis

North America Rapid Infusers Market

North America is a leading market for rapid infusers accounting for over US$ 265 million in 2019. Access to cutting-edge healthcare technology, strict healthcare regulations, and improvements to patient care are key factors positively influencing the market.

Download a Comprehensive Report Snapshot

Lifestyle-based diseases and cases of trauma and injuries are key factors driving the demand for rapid infusers for healthcare facilities in North America, with significant market share accounted for the United States.

Also, the North America rapid infusers market is likely to benefit from frequent tech innovations, enabling offerings to cater to patients with varying healthcare needs. Also, North America is home to a number of market players which helps to consolidate market positioning.

Request a sample specific to North America market

Europe Rapid Infusers Market

Europe is the second largest market for rapid infusers following North America. Robust healthcare infrastructure is an important factor contributing to adoption of rapid infusers, especially in major countries of the European Union.

The requirements for cost-containment in healthcare facilities and the growing number of surgical procedures being carried out in the region will drive long-term growth of the rapid infusers market in Europe.

Also, the rising demand for healthcare in home settings not only in the EU, but also in emerging central and east Europe markets are anticipated to generate opportunities for players in the years to come.

Request a sample specific to Europe market

East Asia Rapid Infusers Market

East Asia is a fairly prominent market for rapid infusers, reflecting faster than average growth. Rising awareness among healthcare professionals and patients about healthcare quality and safety standards are driving the adoption of rapid infusers.

Led by China, the vast population base of the region, the growth of the middle class, and the expansion of healthcare coverage are expected reflect a positive growth trajectory.

Also, East Asia has emerged as a leading MedTech center with low cost labor, improvements in intellectual property protections, and major investments in terms of research and innovations.

The penetration of rapid infusers in the region remains fairly low, which allows for significant market expansion opportunities. Low competition from domestic players will also aid market leaders.

Category-wise Insights

Higher Demand for Trolley Mounted Devices

Rapid infusers can be largely classified on the basis of product type into trolley mounted devices, handheld devices and accessories. The trolley mounted devices segment is projected to reach approximately 70% of the overall market share by the end of the assessment period.

The demand for trolley based rapid infusion devices for the forecast period has largely been attributed to ease of use and portability, which has made it an ideal choice for operations in professional healthcare settings.

Reusable Rapid Infusers Top-selling Category

In terms of usability, rapid infuser devices are categorized into single-use and reusable variants. Of these, reusable rapid infuser devices are expected to remain highly sought-after for the foreseeable future, at a valuation of more than US$ 497 million by 2030.

Reusable rapid infusers are largely in demand owing to cost benefits to healthcare facilities. However, the ongoing pandemic is likely to affect sales of reusable options in favor of single-use alternatives in the short-term.

Hospitals Remain Primary End-users

Rapid infusers play important roles in hospitals, ambulatory surgical centers, and specialty clinics. Hospitals as end-users, account for more than 60% of the market share, while also estimated to reflect a relatively faster growth rate through 2030.

Investments from the public and private sector into healthcare infrastructure, in addition to adoption of rapid infusers in premium hospitals, intensive care units, and emergency care units is a major factor driving growth. 

Rapid Infuser Manufacturers and Competitive Landscape

Leading players in the moderately consolidated rapid infusers market have been largely focused on product research and development strategies to widen their portfolios. Market players are also seeking strategic acquisitions and mergers to bolster geographic presence and capacity expansion.

For instance, in September 2020, 410 Medical announced the clearance from the FDA for its LifeFlow rapid infuser device. The product is capable of delivering a liter of crystalloid fluids for applications in the healthcare sector.

Belmont Instrument Corp has unveiled a new variant of its RI-2 rapid infuser, which uses a proprietary patented induction heating technology, which can prove critical in the treatment of hypothermia, during surgery, and other instances of major blood loss.

The company has also announced the acquisition of MTRE Advanced Technologies Ltd. including its Mennen Medical Ltd product lines. The acquisition is likely to bolster rapid infuser technology for its portfolio.

Genentech has announced the approval from the European Medicines Agency (EMA) for its supplemental biologics license, which covers a 2-hour Ocrevus infusion time, for applications in terms of progressive or relapsing multiple sclerosis.

These developments are likely to positively influence the rapid infuser industry through the forecast period.

Other leading players in the market include:

• 3M
• GE Healthcare Inc.
• Stryker Corporation
• ZOLL Medical Corporation
• Smith’s Group plc
• Teleflex Incorporated
• Becton, Dickinson and Company
• Soma Technology Inc.
• Smisson-Cartledge Biomedical

The list is only indicative – full list of rapid infusers market key players is available upon request.

Rapid Infusers Industry Report: Scope

Key Questions Answered by the Report

• What is the size of the rapid infusers market?

  The global rapid infusers market is set to reach a valuation of US$ 817 million in 2020. The rapid infusers market is estimated to rise steadily at 4.6% CAGR between 2020 and 2030.

• Which is the largest market for rapid infusers?

  The US is the largest market for rapid infusers, owing to the strong presence of leading market players.

• Which are the top companies in global rapid infusers market?

  3M, GE Healthcare Inc., Stryker Corp., ZOLL Medical Corp., Smith’s Group Plc, Teleflex Inc., Belmont Instrument Corporation, Becton, Dickinson and Company, Soma Technology Inc., 410 Medical, Smisson-Catledge Biomedical are some of the major players in the rapid infusers market.

• What are the applications of rapid infusers?

  Rapid infusers products are used in healthcare facilities to infuse warmed blood or crystalloid fluids for patients with for military and civilian clinicians around the world.

• What are the prospects for the East Asia rapid infusers market?

  Countries in the East Asia region are reflecting relatively faster growth than other regional markets on the back of growing investments into medical tourism and favorable government policies towards healthcare infrastructure.

• What is the near-term competitive outlook of the global rapid infusers market?

  The global rapid infusers market is moderately consolidated, with investments into product development, with strategic acquisitions and mergers gaining traction.

Enquiry before Buying

• Is this research conducted by Future Market Insights?

  Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst.

• What research methodology is followed by FMI?

  FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions.

• Who are the respondents for primary research?

  FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.

• What are the sources of secondary research?

  FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request. 

• Is a sample of this report available for evaluation?

  Yes, you can request a sample and it will be sent to you through an email.

• How can I buy this report?

  FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.

Key Segments

Product Type

• Trolley Mounted Devices
• Handheld Devices
• Accessories

Usability

• Single Use
• Reusable

End User

• Hospitals
• ASCs
• Specialty Clinics

Region

• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Argentina, and Rest of Latin America)
• Europe (Germany, Italy, France, UK, Spain, Benelux, Russia, Rest of Europe)
• East Asia (China, Japan, South Korea)
• South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia)
• Oceania (Australia and New Zealand)
• Middle East & Africa (GCC Countries, Northern Africa, South Africa, Rest of MEA)